FDA’s Orthopaedic and Rehabilitation Devices Panel voted 4-2 with two abstentions that VertiFlex Inc.’s Superion interspinous spacer’s benefits outweigh its potential risks to treat lumbar spinal stenosis. If approved by the agency, it would be the second such interspinous device to reach the U.S. market following Medtronic PLC’s X-Stop spacer, which was approved by FDA in 2005 over the orthopedic panel’s objections. (See Also see "St. Francis’ X-Stop Gets FDA Green Light To Treat Lumbar Spinal Stenosis" - Medtech Insight, 28 November, 2005.).
Agency reviewers acknowledged that Superion proved to be non-inferior to X-Stop in clinical trial data provided by the company, but expressed concern with the higher rate of spinous process fractures...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?